<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Putu Virgina Angga Saraswati</style></author><author><style face="normal" font="default" size="100%">Mahrus Abdur Rahman</style></author><author><style face="normal" font="default" size="100%">Risky Vitria Prasetyo</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of Magnesium Supplementation on the Carotid Intima Media Thickness in Children with Chronic Kidney Disease and Hyperphosphatemia: A Double-blind Randomized Clinical Trial</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Carotid Intima Media Thickness</style></keyword><keyword><style  face="normal" font="default" size="100%">Children</style></keyword><keyword><style  face="normal" font="default" size="100%">Chronic Kidney Disease</style></keyword><keyword><style  face="normal" font="default" size="100%">Hyperphosphatemia</style></keyword><keyword><style  face="normal" font="default" size="100%">Magnesium</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">October 2024</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">16</style></volume><pages><style face="normal" font="default" size="100%">1056-1061</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background:&lt;/strong&gt; Hyperphosphatemia has been emphasized to be a significant risk factor for vascular calcification in CKD patients. This study aims to investigate the effect of magnesium supplementation on the reduction of phosphate levels and carotid intima media thickness in children as predictor on vascular calcification with CKD and hyperphosphatemia, compared to a placebo.&lt;strong&gt; Methods:&lt;/strong&gt; A randomized, double-blind, placebo-controlled trial was conducted at Pediatric Ward and Outpatient Clinic of Pediatric Nephrology in our setting during October-March 2023. We compared oral magnesium supplementation (6 mg/kg body weight/day for two months) with a placebo in children with CKD and hyperphosphatemia (ages 1-18 years old). Patients who were on dialysis and had serum magnesium levels of &amp;lt;1.6 mg/dL and &amp;gt;2.4 mg/dL, and were allergic to magnesium supplementation were excluded. A paired T-test and the Wilcoxon signed-rank test were used for statistical analysis. &lt;strong&gt;Results:&lt;/strong&gt; We collected 25 children in the experimental group and 25 children in the placebo group. Phosphate levels were decreased in both the magnesium supplementation and placebo groups (6.1 ± 0.79 to 6.0 ± 0.63 mg/dL; p-value = 0.852 and 6.01 ± 0.55 to 5.8 ± 0.64 mg/dL; p-value=0.365). However, when compared between groups, the reductions were not significantly different (0.1 vs 0.21; p-value=0.935). A significant improvement was found in carotid intima media thickness in both groups (0.05±0.01 to 0.05±0.01; p-value=0.000 and 0.05±0.01 to 0.05±0.01; p-value=0.000), and the reductions were significantly different (0.01 vs 0.01; p-value=0.000). &lt;strong&gt;Conclusion: &lt;/strong&gt;Magnesium supplements have considerably lower phosphate levels and significantly reduced the thickness on carotid intima media in children with CKD and hyperphosphatemia.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">5</style></issue><work-type><style face="normal" font="default" size="100%">Original Article</style></work-type><section><style face="normal" font="default" size="100%">1056</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Putu Virgina Angga Saraswati&lt;sup&gt;1,2&lt;/sup&gt;, Mahrus Abdur Rahman&lt;sup&gt;1,2&lt;/sup&gt;, Risky Vitria Prasetyo&lt;sup&gt;1,2*&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Child Health, Dr Soetomo General Academic Hospital, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Child Health, Faculty of Medicine- Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Glabela Christiana Pandango</style></author><author><style face="normal" font="default" size="100%">Bambang Purwanto</style></author><author><style face="normal" font="default" size="100%">Risky Vitria Prasetyo</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of Magnesium Supplementation on Kidney Function and Phosphate Levels in Children with Chronic Kidney Disease and Hyperphosphatemia: A Double-blind Randomized Clinical Trial</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Children</style></keyword><keyword><style  face="normal" font="default" size="100%">Chronic Kidney Disease</style></keyword><keyword><style  face="normal" font="default" size="100%">Hyperphosphatemia</style></keyword><keyword><style  face="normal" font="default" size="100%">Kidney Function.</style></keyword><keyword><style  face="normal" font="default" size="100%">Magnesium</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">June 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">253-257</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background: &lt;/strong&gt;Pediatric patients with chronic kidney disease (CKD) who have hyperphosphatemia may experience further deterioration in kidney function. This study aims to investigate the effect of magnesium supplementation on the reduction of phosphate levels and improvement of kidney function in children with CKD and hyperphosphatemia, compared to a placebo. &lt;strong&gt;Methods: &lt;/strong&gt;A randomized, double-blind, placebocontrolled trial was conducted at Pediatric Ward in our setting during March-July 2022. We compared oral magnesium supplementation (6 mg/kg body weight/day for two months) with a placebo in children with CKD and hyperphosphatemia (ages 1-18 years old). Patients who were on dialysis and had serum magnesium levels of &amp;lt;1.6 mg/dL and &amp;gt;2.4 mg/dL, and were allergic to magnesium supplementation were excluded. A paired T-test and the Wilcoxon signed-rank test were used for statistical analysis. &lt;strong&gt;Results:&lt;/strong&gt; We collected 31 children in the experimental group and 29 children in the placebo group. Phosphate levels were decreased in both the magnesium supplementation and placebo groups (5.4 ± 0.9 to 4.8 ± 1.1 mg/dL; &lt;em&gt;p&lt;/em&gt;-value = 0.001 and 5.1 ± 0.6 to 4.3 ± 1.2 mg/dL; &lt;em&gt;p&lt;/em&gt;-value=0.003). However, when compared between groups, the reductions were not significantly different (0.7 vs 0.8; &lt;em&gt;p&lt;/em&gt;-value=0.935). A significant improvement was found in kidney function in both groups using estimated Glomerular Filtration Rate (eGFR) (83.4±25.3 to 118.8±52; &lt;em&gt;p&lt;/em&gt;-value=&amp;lt;0.001 and 86.3±28.1 to 96.9 ± 35.8; p-value=0.004), and the reductions were significantly different (35.4 vs 10.7; &lt;em&gt;p&lt;/em&gt;-value=0.045).&lt;strong&gt; Conclusion: &lt;/strong&gt;Magnesium supplements have considerably lower phosphate levels and markedly improved kidney function in children with CKD and hyperphosphatemia.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Original Article </style></work-type><section><style face="normal" font="default" size="100%">253</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Glabela Christiana Pandango&lt;sup&gt;1&lt;/sup&gt;, Bambang Purwanto&lt;sup&gt;2&lt;/sup&gt;, Risky Vitria Prasetyo&lt;sup&gt;1,*&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Child Health, Faculty of Medicine Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Physiology, Faculty of Medicine Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Patnaree Wongmanit</style></author><author><style face="normal" font="default" size="100%">Parunkul Tungsukruthai</style></author><author><style face="normal" font="default" size="100%">Pratya Phetkate</style></author><author><style face="normal" font="default" size="100%">Daraporn Rungprai</style></author><author><style face="normal" font="default" size="100%">Sucharat Tungsukruthai</style></author><author><style face="normal" font="default" size="100%">Ouppatham Supasyndh</style></author><author><style face="normal" font="default" size="100%">Kusuma Sriyakul</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Safety Assessment of Supplementation with Cymbopogon citratus Stapf. (Lemongrass) Extract in Patients with Chronic Kidney Disease Stage 3: A Preliminary 90-Days Prospective Study</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Chronic Kidney Disease</style></keyword><keyword><style  face="normal" font="default" size="100%">CKD stage 3</style></keyword><keyword><style  face="normal" font="default" size="100%">Cymbopogon citratus Stapf.</style></keyword><keyword><style  face="normal" font="default" size="100%">Lemongrass</style></keyword><keyword><style  face="normal" font="default" size="100%">Safety</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">December 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">976-986</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background: &lt;/strong&gt;Chronic kidney disease is a major public health issue, and due to resource constraints, many can't access dialysis. &lt;em&gt;C. citratus&lt;/em&gt;, lemongrass is globally prevalent and known to increase urine output without toxicity.&lt;strong&gt; Objective:&lt;/strong&gt; To examine the safety of &lt;em&gt;C. citratus&lt;/em&gt; in patients with CKD stage 3. &lt;strong&gt;Materials and Methods:&lt;/strong&gt; The major compound of &lt;em&gt;C. citratus&lt;/em&gt; was analyzed using high-performance liquid chromatography (HPLC). 64 patients were enrolled and randomly assigned to control or &lt;em&gt;C. citratus&lt;/em&gt; groups. The control group received a placebo, whereas the &lt;em&gt;C. citratus&lt;/em&gt; group received 900 mg of &lt;em&gt;C. citratus&lt;/em&gt; daily for 90 days. All participants were examined BUN, Scr, Cys-C, and eGFR, liver functions, RBC, HCT, Na+, K+, Cl-, and HCO3, and other biochemical parameters. &lt;strong&gt;Results:&lt;/strong&gt; HPLC showed &lt;em&gt;C. citratus&lt;/em&gt; contains of phenolic compounds. Clinically, &lt;em&gt;C. citratus &lt;/em&gt;group had no notable side effects on T-Bil, AST, ALT and ALP. Also, maintained eGFR, SCys-C, K+ and Cl level. The level of blood Na+ was significant increase at day 30 (p &amp;lt; 0.05). The control group had a significant decrease in eGFR and HCO3 levels (p &amp;lt; 0.05) and a significant increase of Cl- and SCys-C. In addition, no statistical differences had found between groups in eGFR, BUN, Cr, Na&lt;sup&gt;+&lt;/sup&gt;, K&lt;sup&gt;+&lt;/sup&gt;, HCO3, PO4, RBC and HCT levels. Throughout the 90 days, no drug allergies or side effects were reported. &lt;strong&gt;Conclusion:&lt;/strong&gt; Dietary supplementation with &lt;em&gt;C. citratus&lt;/em&gt; may have a favorable effect on delaying the course of CKD and is safe to use for patients with CKD stage 3.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">6</style></issue><work-type><style face="normal" font="default" size="100%">Original Article</style></work-type><section><style face="normal" font="default" size="100%">976</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Patnaree Wongmanit&lt;sup&gt;1&lt;/sup&gt;, Parunkul Tungsukruthai&lt;sup&gt;1&lt;/sup&gt;, Pratya Phetkate&lt;sup&gt;1&lt;/sup&gt;, Daraporn Rungprai&lt;sup&gt;2&lt;/sup&gt;, Sucharat Tungsukruthai&lt;sup&gt;3&lt;/sup&gt;, Ouppatham Supasyndh&lt;sup&gt;4&lt;/sup&gt;, Kusuma Sriyakul&lt;sup&gt;1,&lt;/sup&gt;*&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Integrative Medicine, Chulabhorn International College of Medicine, Thammasat University (Rangsit Campus), Pathum Thani, 12120, THAILAND.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Faculty of Pharmacy, Silpakorn University (Sanamchandra Palace Campus), Nakhon Pathom, 73000, THAILAND.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Division of Health and Applied Sciences, Faculty of Science, Prince of Songkla University, Hat Yai, Songkhla 90110, THAILAND.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Faculty of Medicine, Kasetsart University, Chatuchak, Bangkok 10900, THAILAND.&lt;/p&gt;
</style></auth-address></record></records></xml>